| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Pathology and Laboratory Medicine, Joseph Stokes, Jr., Research Institute and Biesecker Pediatric Liver Center, Children’s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA 19104;
Department of Pathology, Harvard Medical School, Boston, MA 02115;
Section of Molecular Genetics and Microbiology and Institute of Cellular and Molecular Biology, University of Texas, Austin, TX 78712;
Department of Adult Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115; and
¶ Department of Immunology, Mayo Clinic, Rochester, MN 55095
Islet allografts are subject to rapid rejection through host cellular immune responses involving mononuclear cell recruitment and tissue injury. Interruption of leukocyte recruitment through chemokine receptor targeting is of therapeutic benefit in various experimental models, but little is known about the contribution of chemokine pathways to islet allograft rejection. We found that murine islets produce monocyte chemoattractant protein-1 (MCP-1; CCL2) in vitro and that islet allograft rejection was associated with intragraft expression of MCP-1 and its receptor, CCR2. We therefore investigated whether MCP-1 and CCR2 are required for the rejection of fully MHC-disparate islet allografts. Wild-type mice treated with blocking anti-MCP-1 mAb plus a brief, subtherapeutic course of rapamycin had long-term islet allograft survival, in contrast to the effect of treatment with either mAb or rapamycin alone. CCR2-/- mice treated with rapamycin also maintained islet allografts long-term. Both MCP/CCR2- and rapamycin-sensitive signals were required for maximal proliferation of alloreactive T cells, suggesting that MCP-1/CCR2 induce rejection by promoting alloreactive T cell clonal expansion and homing and migration. Prolonged islet allograft survival achieved by blockade of the MCP-1/CCR2 pathway plus rapamycin therapy was accompanied by a mononuclear cell infiltrate expressing the inhibitory receptor, programmed death-1 (PD-1), and its ligand (PD-L1, B7-H1), and prolongation of islet allograft survival was abrogated by anti-PD-L1 mAb therapy. These data show that the blockade of MCP-1 binding to CCR2 in conjunction with subtherapeutic immunosuppression can have profound effects on islet allograft survival and implicate the expression of the PD-1/PD-L1 pathway in the regulation of physiologic responses in vivo.
Related articles in The JI:
This article has been cited by other articles:
|
|
 |
|
  J. A Belperio and A. Ardehali Chemokines and Transplant Vasculopathy Circ. Res., August 29, 2008; 103(5): 454 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Wang, H. Dai, N. Wan, Y. Moore, and Z. Dai The Role for Monocyte Chemoattractant Protein-1 in the Generation and Function of Memory CD8+ T Cells J. Immunol., March 1, 2008; 180(5): 2886 - 2893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chen, N. Zhang, S. Fu, B. Schroppel, Q. Guo, A. Garin, S. A. Lira, and J. S. Bromberg CD4+CD25+ Regulatory T-Cells Inhibit the Islet Innate Immune Response and Promote Islet Engraftment. Diabetes, April 1, 2006; 55(4): 1011 - 1021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Zhu, I. Guleria, A. Khosroshahi, T. Chitnis, J. Imitola, M. Azuma, H. Yagita, M. H. Sayegh, and S. J. Khoury Differential Role of Programmed Death-Ligand 1 and Programmed Death-Ligand 2 in Regulating the Susceptibility and Chronic Progression of Experimental Autoimmune Encephalomyelitis J. Immunol., March 15, 2006; 176(6): 3480 - 3489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wang, R. Han, I. Lee, A. S. Hancock, G. Xiong, M. D. Gunn, and W. W. Hancock Permanent Survival of Fully MHC-Mismatched Islet Allografts by Targeting a Single Chemokine Receptor Pathway J. Immunol., November 15, 2005; 175(10): 6311 - 6318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Tao, L. Wang, R. Han, T. Wang, Q. Ye, T. Honjo, T. L. Murphy, K. M. Murphy, and W. W. Hancock Differential Effects of B and T Lymphocyte Attenuator and Programmed Death-1 on Acceptance of Partially versus Fully MHC-Mismatched Cardiac Allografts J. Immunol., November 1, 2005; 175(9): 5774 - 5782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Lee, L. Wang, A. D. Wells, M. E. Dorf, E. Ozkaynak, and W. W. Hancock Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor J. Exp. Med., April 4, 2005; 201(7): 1037 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Schroppel, N. Zhang, P. Chen, D. Chen, J. S. Bromberg, and B. Murphy Role of Donor-Derived Monocyte Chemoattractant Protein-1 in Murine Islet Transplantation J. Am. Soc. Nephrol., February 1, 2005; 16(2): 444 - 451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Schroppel, N. Zhang, P. Chen, W. Zang, D. Chen, K. L. Hudkins, W. A. Kuziel, R. Sung, J. S. Bromberg, and B. Murphy Differential Expression of Chemokines and Chemokine Receptors in Murine Islet Allografts: The Role of CCR2 and CCR5 Signaling Pathways J. Am. Soc. Nephrol., July 1, 2004; 15(7): 1853 - 1861. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
